Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,longTermDebt,shortTermInvestments,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,investments,totalCashflowsFromInvestingActivities,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,PSH.DE,8922300.0,250982000,678280,,-1492232,,-1492232,487281,0,-1165561,-1165561,,-297388,,,,0,0,1165561,0,-326671,,-1492232,-1492232,866810.0,5636614.0,881716.0,9789110.0,10670826.0,51927005.0,-49275644.0,1501135.0,9131977.0,881716.0,1501135.0,192849.0,9611167.0,398188.0,464875.0,,,55557.0,6342387.0,68102.0,5977697.0,5182565.0,-1159822.0,60583.0,-13449.0,364690.0,161617.0,,,,8729451.0,en-US,US,EQUITY,False,Delayed Quote,EUR,SERNOVA CORP.,-0.06878526,326470688,21.190475,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,4,0.89,1630577465,0.029999971,0.88,0.91,0.88,33000,GER,de_market,3.4883687,0.88 - 0.91,0.86,0.862,0.89,finmb_704549,XETRA,Sernova Corp.,CAD,19237,21617,0.09799999,0.123737365,0.792 - 1.39,-0.5,-0.35971224,0.792,1.39,-0.018,0.042,0.88645715,0.0035428405,0.0039966293,0.95574087,-0.06574088,1.58,,,1.39,0.792,0.8865,0.9557,19.24k,21.62k,250.98M,,250.39M,2.45%,0.12%,,,,,,,,,,,0.00%,,,,,"Oct 31, 2020","Jan 31, 2021",0.00%,0.00%,-42.43%,-80.56%,,,,,-4.9M,-5.45M,-0.0180,,9.13M,0.04,,,10.90,0.04,-3.99M,-2.6M,Value,N6G 4X8,Healthcare,"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.",London,877 299 4603,ON,1577750400,Canada,http://www.sernova.com,86400,The Stiller Centre,519 858 5099,Medical Devices,700 Collip Circle Suite 114
t-1,PSH.DE,3228019.0,250982000,486279,,-1030536,,-1030536,434767,0,-921046,-921046,,-25864,,,,0,0,921046,0,-109490,,-1030536,-1030536,916818.0,5737733.0,1580687.0,4144837.0,5725524.0,44640757.0,-47783412.0,1549759.0,3949412.0,878075.0,1549759.0,203423.0,4605283.0,506767.0,529388.0,702612.0,,167725.0,2975393.0,-71654.0,3542975.0,3851387.0,-1083746.0,72556.0,-21514.0,-557816.0,-200323.0,2000000.0,1959740.0,-9766.0,3727208.0,en-US,US,EQUITY,False,Delayed Quote,EUR,SERNOVA CORP.,-0.06878526,326470688,21.190475,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,4,0.89,1630577465,0.029999971,0.88,0.91,0.88,33000,GER,de_market,3.4883687,0.88 - 0.91,0.86,0.862,0.89,finmb_704549,XETRA,Sernova Corp.,CAD,19237,21617,0.09799999,0.123737365,0.792 - 1.39,-0.5,-0.35971224,0.792,1.39,-0.018,0.042,0.88645715,0.0035428405,0.0039966293,0.95574087,-0.06574088,1.58,,,1.39,0.792,0.8865,0.9557,19.24k,21.62k,250.98M,,250.39M,2.45%,0.12%,,,,,,,,,,,0.00%,,,,,"Oct 31, 2020","Jan 31, 2021",0.00%,0.00%,-42.43%,-80.56%,,,,,-4.9M,-5.45M,-0.0180,,9.13M,0.04,,,10.90,0.04,-3.99M,-2.6M,Value,N6G 4X8,Healthcare,"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.",London,877 299 4603,ON,1577750400,Canada,http://www.sernova.com,86400,The Stiller Centre,519 858 5099,Medical Devices,700 Collip Circle Suite 114
t-2,PSH.DE,516038.0,250982000,670257,,-1195580,,-1195580,569922,0,-1240179,-1240179,,-29271,,,,0,0,1240179,0,44599,,-1195580,-1195580,966826.0,5618576.0,1425317.0,1482864.0,2908181.0,41341138.0,-46752876.0,1276026.0,98025.0,748448.0,1276026.0,225971.0,1715384.0,108757.0,427785.0,676869.0,1431152.0,-255833.0,1563736.0,248093.0,21000.0,-329413.0,-933244.0,71209.0,23898.0,600000.0,174968.0,2000000.0,-959905.0,942736.0,966936.0,en-US,US,EQUITY,False,Delayed Quote,EUR,SERNOVA CORP.,-0.06878526,326470688,21.190475,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,4,0.89,1630577465,0.029999971,0.88,0.91,0.88,33000,GER,de_market,3.4883687,0.88 - 0.91,0.86,0.862,0.89,finmb_704549,XETRA,Sernova Corp.,CAD,19237,21617,0.09799999,0.123737365,0.792 - 1.39,-0.5,-0.35971224,0.792,1.39,-0.018,0.042,0.88645715,0.0035428405,0.0039966293,0.95574087,-0.06574088,1.58,,,1.39,0.792,0.8865,0.9557,19.24k,21.62k,250.98M,,250.39M,2.45%,0.12%,,,,,,,,,,,0.00%,,,,,"Oct 31, 2020","Jan 31, 2021",0.00%,0.00%,-42.43%,-80.56%,,,,,-4.9M,-5.45M,-0.0180,,9.13M,0.04,,,10.90,0.04,-3.99M,-2.6M,Value,N6G 4X8,Healthcare,"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.",London,877 299 4603,ON,1577750400,Canada,http://www.sernova.com,86400,The Stiller Centre,519 858 5099,Medical Devices,700 Collip Circle Suite 114
t-3,PSH.DE,2191191.0,250982000,1025084,,-1733214,,-1733214,701458,0,-1726542,-1726542,,-4157,,,,0,0,1726542,0,-6672,,-1733214,-1733214,,5337072.0,992249.0,2191191.0,3183440.0,41305138.0,-45557297.0,1106278.0,427438.0,992249.0,1106278.0,266771.0,2916669.0,132655.0,694934.0,,2031033.0,547483.0,300250.0,262707.0,21000.0,-509828.0,-810078.0,40801.0,-31593.0,329548.0,103738.0,2000000.0,-959905.0,-29298.0,1924420.0,en-US,US,EQUITY,False,Delayed Quote,EUR,SERNOVA CORP.,-0.06878526,326470688,21.190475,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,4,0.89,1630577465,0.029999971,0.88,0.91,0.88,33000,GER,de_market,3.4883687,0.88 - 0.91,0.86,0.862,0.89,finmb_704549,XETRA,Sernova Corp.,CAD,19237,21617,0.09799999,0.123737365,0.792 - 1.39,-0.5,-0.35971224,0.792,1.39,-0.018,0.042,0.88645715,0.0035428405,0.0039966293,0.95574087,-0.06574088,1.58,,,1.39,0.792,0.8865,0.9557,19.24k,21.62k,250.98M,,250.39M,2.45%,0.12%,,,,,,,,,,,0.00%,,,,,"Oct 31, 2020","Jan 31, 2021",0.00%,0.00%,-42.43%,-80.56%,,,,,-4.9M,-5.45M,-0.0180,,9.13M,0.04,,,10.90,0.04,-3.99M,-2.6M,Value,N6G 4X8,Healthcare,"Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.",London,877 299 4603,ON,1577750400,Canada,http://www.sernova.com,86400,The Stiller Centre,519 858 5099,Medical Devices,700 Collip Circle Suite 114
